kabutan

SHIN NIPPON BIOMEDICAL, First Half Ordinary Profit Decreases by 11%, Jul-Sep Ordinary Profit Decreases by 25%

Fri Nov 7, 2025 11:30 am JST Earnings

2395 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. 【J-GAAP】

Earnings Report

SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. <2395> [TSE Prime] announced its financial results at noon (11:30) on November 7th. The consolidated ordinary profit for the cumulative second quarter of the fiscal year ending March 2026 (April to September) decreased 11.0% from the same period last year to 1.62 billion yen. Progress toward the full-year plan of 5.92 billion yen was 27.5%, also falling below the five-year average of 43.6%.

Based on the first-half performance announced by the company and the unchanged full-year plan, our calculation indicates that the consolidated ordinary profit for the October to March period (second half) is expected to decrease 6.9% from the same period last year to 4.30 billion yen.

In the most recent three-month period, from July to September (2Q), the consolidated ordinary profit decreased to 1.11 billion yen, a 25.2% decrease compared to the same period last year. However, the operating profit margin improved from 3.2% in the same period last year to 4.7%.

Kabutan News

Actual Results

Accumulated Results 2nd Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Apr - Sep, 2023 11,884 2,349 3,756 2,966 71.2 53.5 Nov 7, 2023 J-GAAP
Apr - Sep, 2024 12,508 80 1,829 1,331 32.0 28.4 Nov 6, 2024 J-GAAP
Apr - Sep, 2025 14,766 49 1,627 1,061 25.5 27.5 Nov 7, 2025 J-GAAP
YoY +18.1% -38.8% -11.0% -20.3% -20.3%

First Half Results vs. Previous Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Apr - Sep, 2025 Guidance 14,542 -97 1,180 -183 -4.4 20 May 8, 2025 J-GAAP
Apr - Sep, 2025 Results 14,766 49 1,627 1,061 25.5 20 Nov 7, 2025 J-GAAP
Revision Rate +1.5% － +37.9% － －

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Oct - Mar, 2024 19,905 2,905 4,621 3,593 86.3 30 May 8, 2025 J-GAAP
Oct - Mar, 2025 Guidance 18,506 3,501 4,300 2,489 59.8 30 Nov 7, 2025 J-GAAP
YoY -7.0% +20.5% -6.9% -30.7% -30.7%

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2024 26,450 4,162 7,015 5,531 132.9 50 May 8, 2024 J-GAAP
Mar, 2025 32,413 2,985 6,450 4,924 118.3 50 May 8, 2025 J-GAAP
Mar, 2026 Guidance 33,272 3,550 5,927 3,550 85.3 50 May 8, 2025 J-GAAP
YoY +2.7% +18.9% -8.1% -27.9% -27.9%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Jul - Sep, 2024 6,959 225 1,487 1,209 29.0 3.2 Nov 6, 2024 J-GAAP
Oct - Dec, 2024 9,727 1,813 2,309 1,874 45.0 18.6 Feb 5, 2025 J-GAAP
Jan - Mar, 2025 10,178 1,092 2,312 1,719 41.3 10.7 May 8, 2025 J-GAAP
Apr - Jun, 2025 6,477 -340 515 260 6.3 -5.2 Aug 5, 2025 J-GAAP
Jul - Sep, 2025 8,289 389 1,112 801 19.2 4.7 Nov 7, 2025 J-GAAP
YoY +19.1% +72.9% -25.2% -33.7% -33.7%

Related Articles